IMRT 2018
Multicentric Fase II trial
2012 - 2015, N: 170 patients (urethra sparing)
Results (ESTRO 2018)- Follow-up of 18-month good tolerance and toxicity profile of both treatment arms in this study with minimal impact on GU QoL.
Made with FlippingBook - professional solution for displaying marketing and sales documents online